Glaxo Opens Its Clinical Trial Library To Encourage Drug Development
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline, previously punished for holding back key medical information, is making its huge library of clinical trial data available to scientists in an effort promote drug discovery and show that it hides no secrets.
You may also be interested in...
Clinical Data Transparency Would Counter-Balance Off-Label Promotion – NEJM
Giving independent researchers access to patient-level data and requiring public release of clinical study reports would help to offset the weakening of FDA’s oversight caused by industry’s First Amendment victories, a Boston University professor says.
Clinical Data Sharing Could Increase Research Costs, Industry Fears
NIH-funded investigators may direct money away from research to prepare their data for public release; some wonder whether grants should include the cost.
Clinical Trial Data Release: Be Careful What You Wish For, Industry Exec Says
Some advocates and researchers say that data availability could inform repurposing opportunities for products, but a GSK exec cautions that it could just as easily bring a flood of confusing information.